The U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) for a new use: reducing allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adults and children aged 1 year and older with IgE-mediated food allergy. This is a significant step for people who live with the constant worry of accidental exposure to foods like peanuts, milk, or eggs.
Xolair is a biologic drug that works by blocking immunoglobulin E (IgE), a key player in allergic reactions. It has been used for years to treat asthma and other allergic conditions. This new approval means that for some patients, Xolair can be given as a preventive measure to lower the risk of severe reactions if they accidentally eat a food they are allergic to.
The approval is based on clinical trials, though specific results are not detailed in the label. Xolair is given as an injection under the skin, with dosing based on the patient's weight and IgE levels. It is not a cure, and it does not replace the need to avoid allergens. It is also not for emergency treatment of an allergic reaction.
If you or your child have a food allergy, talk to your doctor about whether Xolair might be right for you. Remember, this medication is a preventive tool, not a safety net. You should always carry your epinephrine auto-injector and have an action plan in place.
